Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

Background Evidence supports magnesium sulphate (MgSO4) for women at risk of imminent
birth at< 32–34 weeks to reduce the likelihood of cerebral palsy in the child. MAGnesium …

The aim of our study was to assess the feasibility of implementing a protocol for the use of
magnesium sulfate to prevent cerebral palsy. This retrospective single-center study included …

Abstract Background Magnesium sulphate (MgSO 4) is the only treatment approved for fetal
neuroprotection. No information on its use is available in the absence of a national registry …

El tratamiento con sulfato de magnesio prenatal ha demostrado su eficacia en reducir la
parálisis cerebral en los menores de 32 semanas de edad gestacional. Estudiamos la …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

Abstract Background and Aim: In recent times, survival of preterm infants has improved
drastically. In addition to significant contribution to neonatal mortality, impact of prematurity …

Résumé Objectifs Bien que le bénéfice du sulfate de magnésium à visée neuroprotectrice
en prénatal chez le grand prématuré ait été démontré, il persiste des réticences à son …

Background: Cerebral palsy (CP) is the leading cause of physical disability in childhood.
Despite emerging evidence that the prevalence of CP has begun to decline, approximately …

RESUMO O parto prematuro é um importante fator relacionado com a morbimortalidade
neonatal, e ainda permanece entre as complicações obstétricas mais comuns, apesar dos …